Medtech Companies Looking to Succeed in New Health Economy Must Change How They Innovate, finds PwC’s Health Research Institute

“Embrace failure,” “own the disease,” among PwC’s prescriptions for medtech players

Singapore, 27 November 2013 – Medical technology companies may be losing their competitive edge and are in need of a different approach to innovation in a new outcome-based health economy, according to PwC’s Health Research Institute (HRI) new report, Medtech companies prepare for an innovation makeover.

The report also includes a web-based interactive innovation scorecard to assess medtech companies based on leading innovation practices. Only 14 percent of medtech executives say that they formally manage innovation activities, which is essential to creating new services and business models. And just 17 percent believe their companies are innovation pioneers. The HRI report outlines how medtech companies need to expand their approaches to innovation outside traditional R&D, in order to remain competitive.

Said Abhijit Ghosh, Pharmaceutical & Life Sciences Leader, PwC Singapore,

“These approaches are equally relevant for medtech companies operating in emerging markets so that they can create an edge and increase their market share in these markets which are anticipated to grow at a faster pace than developed markets.”

Key report findings include:

  • The value of a device is no longer solely in the product itself but in a company's ability to help customers solve broader problems.
  • New competitors are staking their claim – at least 18 companies have entered the medtech space and are driving innovation at the pace of technology.
  • New integrated services and business models that address clinician and consumer needs are becoming more important.
  • Medtech executives expect a higher level of innovation over the next three years but lack formal processes to achieve their goals for new services and business models.
  • Medtech companies have been slower to apply new social, mobile, analytic, and cloud (SMAC) technologies than other industries.
  • Medtech companies are looking to open innovation as a key approach to drive future growth.

Said Ajay Sanganeria, Tax Director specialising in Pharmaceutical & Life Sciences, PwC Singapore,

“The concept of collaborative research is also evolving in Asia and it offers perfect opportunity for medtech companies to collaborate and innovate products as well as new business models which are best suited for the Asian market population to tap on the growth opportunities.”



About HRI’s Medical Technology Company Innovation Scorecard

To assess the state of company-level innovation in medtech, HRI undertook its second global survey, and this year, more than 50 companies participated in the research including those doing business in in-vitro diagnostics, disposable medical products, medical equipment, diversified life sciences, implantable devices, as well as other healthcare companies and new players in the field. HRI interviewed more than 30 top executives and conducted a survey in summer 2013 of more than 35 medtech companies, almost half of which reported revenues in excess of 1 billion U.S. dollars.

HRI developed a web-based interactive innovation scorecard to assess medtech companies based on leading practices in innovation. The scorecard is a guide for executives to use as they develop and refine their innovation game plan. Visit HRI's Medical Technology Company Innovation Scorecard microsite to compare scores by company size and geography.

Medtech companies prepare for an innovation makeover is the second in a series of reports on medtech innovation, the first of which focused on global competitiveness.  A full copy of the report and supporting infographics are available for download at


Note: Any citations of this research must be attributed to “PwC’s Health Research Institute.”

About PwC Health Research Institute (HRI)

PwC’s Health Research Institute ( provides new intelligence, perspectives, and analysis on trends affecting health-related industries. The Health Research Institute helps executive decision makers navigate change through primary research and collaborative exchange. Our views are shaped by a network of professionals with executive and day-to-day experience in the health industry. HRI research is not sponsored by businesses, government, or other institutions.


Media Contact
Candy Li, PwC LLP Singapore (Tel: +65 6236 7429 Email: or